November 28, 2023 - ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case

(3)

Global Cancer NGS Reporting Practices

Availability

Retired

Cost

$0.00

Credit Offered

No Credit Offered

Description
Meet the Faculty
Accredited Continuing Education Information
Financial Disclosures

Title: Global Cancer NGS Reporting Practices

Description: Embark on an enlightening journey with our esteemed panel of international experts from Germany, Australia, and the United States as they unravel the intricacies of Cancer NGS reporting practices. Join us for an exclusive and insightful panel discussion that will delve deep into the vital aspects of generating comprehensive and clinically relevant cancer NGS reports.

Key Discussion Points:

🔍 Understanding the Critical Elements: Discover the crucial components necessary to effectively communicate clinically significant findings within a cancer NGS report.

🌍 Global Variances Unveiled: Explore the diverse challenges each geographical area encounters in striving for report standardization, navigating regulatory requirements, and integrating precision medicine into reporting practices.

📚 Implementation Insights: Gain valuable insights into real-world experiences in implementing guidelines and standards within the realm of NGS reporting practices.

Target Audience

All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.

Agenda

Presentation followed by live Q&A.

Learning Objectives

At the conclusion of this session, participants should be able to:

Engage in discussions about the essential elements required for effectively communicating clinically relevant findings within cancer NGS reports.
Identify and discuss the challenges faced by different regions in balancing report standardization, regulatory demands, and the integration of precision medicine.
Articulate and share experiences in the implementation of guidelines and standards in the intricate landscape of NGS reporting practices.

Moderator

A person wearing glasses smilingDescription automatically generated

Manuela Benary, PhD

Bioinformatician, Charité – Universitätsmedizin Berlin, Berlin, Germany

Presenters

Ein Bild, das Person, Mann, Brille, Im Haus enthält.Automatisch generierte Beschreibung

Damian Rieke, MD

Dr. Rieke is a physician and researcher at the Charité Comprehensive Cancer Center and the Department for Hematology, Oncology and Cancer Immunology at Charité - Universitätsmedizin Berlin in Berlin, Germany. As speaker of the platform for personalized cancer medicine at Charité, his main areas of interest include the development of targeted treatment strategies and the targeted use of immune therapeutics as well as their application in clinical routine.

Histone H3 Somatic Cancer Variant Curation Expert Panel - ClinGen | Clinical Genome Resource

Laveniya Satgunaseelan, MBBS BMedSc FRCPA

Dr. Satgunaseelan is a neuropathologist at Royal Prince Alfred Hospital in Sydney, Australia. In addition to her clinical and research work in genomics related to neuropathology, she is also an active member of the Cancer Genomics Consortium (CGC) and co-chairs the ClinGen Histone H3 Somatic Cancer Variant Curation Expert Panel and Solid Tumor Taskforce.

Gordana Raca

Gordana Raca, MD, PhD, FACMG

Dr. Gordana Raca is Director of the Cytogenomics Laboratory in the Center for Personalized Medicine in the Department of Pathology and Laboratory Medicine at Children’s Hospital Los Angeles, and Associate Professor of Clinical Pathology at the Keck School of Medicine at the University of Southern California. Dr. Raca specializes in clinical cytogenetics and molecular diagnostics related to Cancer.

Planning Committee:

Beth Pitel, MS, CG(ASCP)

Gordana Raca, MD, PhD, FACMG

Manuela Benary, PhD

Jason Saliba, PhD

Jane Radford, MHA, CHCP

Claudia Barnett

Continuing Medical Education (CME AMA & CME Other)

Accreditation

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Medical Genetics and Genomics designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country. Non-physicians may request a certificate of attendance for their participation.

Claiming your Educational Credits

Complete the activity and carefully complete the evaluation form. The deadline to claim educational credits is within 30 days of the date of the activity. Educational credit requests after this date will not be accepted.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACMG Education Policies

Please review the policies below regarding the ACMG Education program

All of the relevant financial relationships listed for these individuals have been mitigated.

NAME	ROLE			RELATIONSHIP/ COMPANY
	Planning Member	Presenter Panelist Moderator	Peer Reviewer
Damian Rieke, MD		●		Consultant – Bayer, Bristol Myers Squibb Company, F. Hoffman-La Roche AG
Laveniya Satgunaseelan, MBBS BMedSc FRCPA		●		Nothing to Disclose.
Beth Pitel, MS, CG(ASCP)	●			Advisory Board – Qiagen, LLC
Claudia Barnett	●			Nothing to Disclose.
Gordana Raca, MD, PhD, FACMG	●	●	●	Nothing to Disclose.
Jane Radford, MHA, CHCP	●			Nothing to Disclose.
Jason Saliba, PhD	●			Nothing to Disclose.
Manuela Benary, PhD	●	●		Nothing to Disclose.